2022 American Transplant Congress
Outcomes of ABO-Incompatible Adult Living Donor Liver Transplantation for Patients with Hepatocellular Carcinoma Beyond the Milan Criteria
Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of
*Purpose: Given the organ scarcity, ABO incompatible (ABOi) living donor liver transplantation (LDLT) emerged as a treatment option for hepatocellular carcinoma (HCC) and underlying liver…2021 American Transplant Congress
Outcomes of Downstaging Hepatocellular Carcinoma (HCC) to within Milan Criteria Before Liver Transplantation (LT): A Multicenter Analysis of the “All-comers” Protocol
*Purpose: Patients with HCC meeting UNOS-downstaging (DS) criteria (1 lesion 5.1-8 cm, 2-3 lesions at least one 3.1-5 cm and total tumor diameter (TTD) ≤8…2021 American Transplant Congress
Albumin Level Prior to Liver-Directed Therapy is a Risk Factor of Waitlist Tumor Progression Independent of HCC Burden
Ochsner Health, New Orleans, LA
*Purpose: Milan Criteria, α-fetoprotein (AFP), and MELD score at diagnosis influence prognosis in bridge to transplant (BTT) hepatocellular carcinoma (HCC). With HCC surveillance many patients…2021 American Transplant Congress
Role of Baseline PD-1 Checkpoint Inhibitor Pathway Expression in Bridge to Liver Transplant Hepatocellular Carcinoma
Ochsner Health, New Orleans, LA
*Purpose: Response to first line liver-directed therapy (LDT) in hepatocellular carcinoma (HCC) has important implications in both bridge to transplant (BTT) success as well as…2021 American Transplant Congress
Short Waiting Time is Not Associated with Decrease in Disease-free Survival in Liver Transplant Recipients with HCC
*Purpose: Studies have suggested that shorter waiting times (WT) for liver transplant (LT) in patients with hepatocellular carcinoma (HCC) may be associated with increased HCC…2021 American Transplant Congress
NASH-Related HCC is Associated with Lower Rates of Post-Transplant HCC Recurrence: A Large Database Analysis
Department of Surgery, Thomas Jefferson University, Philadelphia, PA
*Purpose: As incidence of hepatocellular carcinoma (HCC) and Non-Alcoholic Steatohepatitis (NASH) increase, NASH-related HCC is an increasingly common transplant indication. Large-scale studies evaluating transplantation for…2021 American Transplant Congress
Outcomes of DCD Allografts in Liver Transplant Recipients with HCC
*Purpose: Early studies demonstrated inferior survival for liver transplant (LT) recipients with hepatocellular carcinoma (HCC) who received allografts from donation after cardiac death (DCD) donors…2021 American Transplant Congress
Adjuvant Immunotherapy for Liver Transplant Recipients with Hepatocellular Carcinoma Using Donor Liver-derived Natural Killer Cells
1Hiroshima University, Hiroshima, Japan, 2University of Miami, Miami, FL
*Purpose: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and is an indication for liver transplantation (LT). Immunosuppressive regimens currently used after…2021 American Transplant Congress
Waitlist Outcomes for Exception Candidates Following the Implementation of MMaT/250 Score
1Johns Hopkins Medical Institutions, Baltimore, MD, 2Temple University, Philadelphia, PA
*Purpose: Starting in May 2019, exception points were allocated based on DSA-level median-MELD-at-transplant (MMaT/DSA). In February 2020, the exception point system was further modified based…2021 American Transplant Congress
T Cell Repertoire Diversity in HCV-Associated Hepatocellular Carcinoma Patients Waitlisted for Liver Transplantation and Receiving Liver-Directed Therapy
Ochsner Health, New Orleans, LA
*Purpose: T cell receptor (TCR) sequencing in hepatocellular carcinoma (HCC) patients revealed a diverse TCR repertoire in hepatitis B-associated HCC-infiltrating T cells. In this study,…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 23
- Next Page »